Download PDF
Aktuelle Rheumatologie 2017; 42(03): 217-221
DOI: 10.1055/s-0042-114978
Übersichtsarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Labordiagnostik bei metabolischen Knochenerkrankungen – Möglichkeiten und Grenzen

Laboratory Analysis in Metabolic Bone Diseases: Possibilities and Limitations
Uwe Lange
1   Rheumatologie, Klinische Immunologie, Physikalische Medizin und Osteologie, Kerckhoff-Klinik, Universität Gießen, Bad Nauheim
,
Monika Reuss-Borst
2   Facharztpraxis für Innere Medizin, Klinikum Bad Bocklet, Bad Bocklet
› Author Affiliations
Further Information

Publication History

Publication Date:
23 March 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Ein wichtiges Tool in der Diagnostik und Differenzialdiagnostik osteologischer Erkrankungen stellt die Labormedizin dar. So dient das in der S3-Leitlinie Osteoporose empfohlene Basislabor zur Differenzierung zwischen primärer und sekundärer Osteoporose, was aufgrund der therapeutischen Konsequenzen von elementarer Bedeutung ist. Knochenumbaumarker geben zusätzliche Informationen zur Abschätzung der Dynamik des Knochenstoffwechsels. Die Knochenstoffwechselmarker finden vorwiegend als Orientierungshilfe bei der Therapieentscheidung, der Verlaufsbeobachtung unter einer osteospezifischen Medikation und im Compliance-Monitoring Anwendung. Ziel des vorliegenden Beitrages ist die Darlegung der Bedeutung der etablierten osteologischen Labordiagnostik bei metabolischen Knochenerkrankungen im Praxisalltag.

Abstract

Laboratory tests are an important tool in the diagnostic and differential diagnostic investigation of osteologic diseases. As recommended in the German S3 guideline for osteoporosis, a basic laboratory examination is essential for the differentiation between primary and secondary osteoporosis, and of prime importance for initiating an appropriate treatment. Markers of bone turnover may provide additional information regarding the dynamics of bone metabolism. They are mainly used to guide the choice of treatment and the monitoring of treatment response and patient compliance after the initiation of an anti-osteoporosis therapy. This paper aims to describe the significance of the established osteologic laboratory tests for metabolic bone diseases in everyday practice.

Schlüsselwörter

Osteoporose - allgemeines Basislabor - Knochenstoffwechselmarker (Knochenbiomarker)

Key words

osteoporosis - general basic laboratory examinations - markers of bone turnover (bone biomarkers)
 

  • Literatur

  • 1 Scharla S. Stellenwert des allgemeinen Labors in der Diagnostik und Verlaufskontrolle der Osteoporose. Osteologie 2015; 24: 211-214
    PubMedGoogle Scholar
  • 2 Fachinformation Prolia. www.fachkreise.amgen.de
    PubMed
  • 3 Scharla S, Lempert U. Case-Report: Hypercalcemia after Vitamin D supplementation with 20.000 IU every two weeks. Osteoporos Int 2013; 24 (Suppl. 01) S322
    PubMedGoogle Scholar
  • 4 Scharla S. Tumorhyperkalzämie. Nieren- und Hochdruckkrankheiten 2013; 42: 445-450
    PubMedGoogle Scholar
  • 5 Fuleihan GE, Bouillon R, Clarke B. et al. Serum 25-Hydroxyvitamin D Levels: Variability, Knowledge Gaps, and the Concept of a Desirable Range. J Bone Min Res 2015; 30: 1119-1133
    CrossrefPubMedGoogle Scholar
  • 6 Scharla S, Lampert U. Variabilität der 25-Hydroxyvitamin D-Bestimmung in Abhängigkeit der Methodik. Osteologie 2012; 21: A48-A49
    PubMedGoogle Scholar
  • 7 Vanbillemont G, Bogaert V, De Bacquer D. et al. Polymorphisms of the SHGB gene contribute to the interindividual variation of sex steroid hormone blood levels in young, middle-aged, and elderly men. Clin Endocrinol 2009; 70: 303-310
    CrossrefPubMedGoogle Scholar
  • 8 Crabbe P, Bogaert V, De Bacquer D. et al. Part of the interindividual variation in serum testosterone levels in healthy men reflects differences in androgen sensitivity and feedback set point: contribution of the androgen receptor polyglutamine tract polymorphism. J Clin Endocrinol Metab 2007; 92: 3604-3610
    CrossrefPubMedGoogle Scholar
  • 9 Van der Veer E, van der Goot W, de Monchy JGR. et al. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 2012; 67: 431-439
    CrossrefPubMedGoogle Scholar
  • 10 Delmas PD, Eastell R, Garnero P. et al. Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Osteoporosis Int 2000; 11 (Suppl. 06) S2-S17
    CrossrefPubMedGoogle Scholar
  • 11 Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin Chem 1999; 45 8 Pt 2 1359-1368
    PubMedGoogle Scholar
  • 12 Halleen JM, Alatalo SL, Janckila AJ. et al. Serum tartrate-resistand acid Phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 2011; 47: 597-600
    PubMedGoogle Scholar
  • 13 Biegelmayer C, Dimai HP, Gasser RW. et al. Biomarkers of bone turnover in diagnosis and therapy of osteoporosis: a consensus advice from an Austrian working group. Wien Med Wochenschr 2012; 162: 464-477
    CrossrefPubMedGoogle Scholar
  • 14 Schwetz V, Obermayer-Pietsch B. Knochenumbaumarker. Übersicht und klinische Bedeutung. Osteologie 2015; 24: 215-218
    PubMedGoogle Scholar
  • 15 Obermayer-Pietsch B, Schwetz V. Biochemische Marker des Knochenstoffwechsels und ihre Bedeutung. Z Rheumatol 2016; 75: 451-458
    CrossrefPubMedGoogle Scholar
  • 16 Akesson K, Kakonen SM, Josefsson PO. et al. Fracture-induced changes in bone turnover: a potential confounder in the use of biochemical markers in osteoporosis. J Bone Miner Metab 2005; 23: 30-35
    PubMedGoogle Scholar
  • 17 Bauer DC, Sklarin PM, Stone KL. et al. Biochemical markers of bone turnvover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J Bone Miner Res 1999; 14: 1404-1410
    CrossrefPubMedGoogle Scholar
  • 18 Lenora J, Ivaska KK, Obrant KJ. et al. Prediction of bone loss using biochemical markers of bone turnover. Osteoporosis Int 2007; 18: 1297-1305
    CrossrefPubMedGoogle Scholar
  • 19 Garnero P, Sornay-Rendu E, Claustrat B. et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000; 15: 1526-1536
    CrossrefPubMedGoogle Scholar
  • 20 van Daele PL, Seibel MJ, Burger H. et al. Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study. BMJ 1996; 312: 482-483
    CrossrefPubMedGoogle Scholar
  • 21 Black DM, Delmas PD, Eastell R. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822
    CrossrefPubMedGoogle Scholar
  • 22 Saag K, Lindsay R, Kriegman A. et al. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 2007; 40: 1238-1243
    CrossrefPubMedGoogle Scholar
  • 23 Bauer DC, Garnero P, Hochberg MC. et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 2006; 21: 292-299
    PubMedGoogle Scholar
  • 24 Cummings SR, San Martin J, McClung MR. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765
    CrossrefPubMedGoogle Scholar
  • 25 Naylor KE, Jacques RM, Paggiosi M. et al. Response of bone turnover markers to three oral Bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporos Int 2015; DOI: 10.1007/s00198-015-3145-7.
    PubMedGoogle Scholar
  • 26 Black DM, Schwartz AV, Ensrud KE. et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Longterm Extension (FLEX): a randomized trial. JAMA 2006; 296: 2927-2938
    CrossrefPubMedGoogle Scholar
  • 27 Black DM, Reid IR, Boonen S. et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012; 27: 243-254
    CrossrefPubMedGoogle Scholar